Generic placeholder image

Current Radiopharmaceuticals


ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Evaluation of 177Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy

Author(s): Sudipta Chakraborty, Lajos Balogh, Tapas Das, András Polyák, Gábor Andócs, Domokos Máthé, Réka Király, Julianna Thuróczy, Pradip R. Chaudhari, Gyozo A. Jánoki, Gergely Jánoki, Sharmila Banerjee and M. R.A. Pillai

Volume 9, Issue 1, 2016

Page: [64 - 70] Pages: 7

DOI: 10.2174/1874471008666150312164255

Price: $65


177Lu-EDTMP is currently being investigated as a potential agent for providing palliative care to the patients suffering from bone pain due to metastatic skeletal carcinoma. The present article describes the evaluation of 177Lu-EDTMP complex in four different canine patients with different types of primary and metastatic skeletal lesions with respect to its pharmacokinetic properties, dosimetry and therapeutic efficacy. The dogs were treated with a dose of ~44.4 MBq (1.2 mCi) per kg body weight of 177Lu-EDTMP, synthesized in-house with high radiochemical purity (98.8 ± 0.4 %) and excellent in vitro stability. The radiopharmaceutical showed favourable pharmacokinetic properties, such as, preferential accumulation at skeletal lesion sites and fast clearance from blood and other non-target organs through urinary route. The administered dose of the radiopharmacutical showed excellent therapeutic efficacy in case of a dog suffering from skeletal metastasis originating from primary tumor elsewhere. On the other hand, two of the remaining three patients with primary bone cancer showed stable disease intially with palliative effect. The fourth patient having metal implant induced osteosarcoma with severe limb oedema did not show any response to the treatment

Keywords: 177Lu-EDTMP, canine patient, pain palliation, primary bone cancer, skeletal metastases, therapeutic efficacy.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy